For long time, routine clinical practice for the management of patients with PRL excess has been based on the assumption that low or undetectable PRL levels during treatment with dopamine agonists might be associated with a better prognosis and long-term rescue from the pituitary tumours. Here, PRL is linked to pituitary tumor.